CAMBRIDGE, Mass., Nov. 13,
2024 /PRNewswire/ -- NeuroBo Pharmaceuticals,
Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company
focused on transforming cardiometabolic diseases, today announced
participation in the following investor conferences in
November:
- November 14: Life Science Virtual Investor Forum.
Hyung Heon Kim, President and Chief
Executive Officer and Marshall H.
Woodworth, Chief Financial Officer, will present a company
overview on Thursday, November 14, at
1:00 pm ET. Management will also be
available for one-on-one meetings during the event. Interested
parties who would like to listen to the Company's presentation or
request a meeting can do so after registering for the conference
at https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-6.
- November 21: Winter 2024 Investor Summit Virtual.
Mr. Kim and Mr. Woodworth will present a company overview on
Thursday, November 21, at
11:00 am ET, at this virtual summit.
To listen to the presentation or to schedule one-on-one meetings,
interested parties can register at:
https://www.webcaster4.com/Webcast/Page/3075/51588.
To schedule a meeting with management outside of these events,
investors can contact Michael Miller
at mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo
Pharmaceuticals, Inc. is a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases. The
company is currently developing DA-1726 for the treatment of
obesity, and is developing DA-1241 for the treatment of Metabolic
Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel
oxyntomodulin (OXM) analogue that functions as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists. DA-1241 is a
novel G-protein-coupled receptor 119 (GPR119) agonist that promotes
the release of key gut peptides GLP-1, GIP, and PYY. In
pre-clinical studies, DA-1241 demonstrated a positive effect on
liver inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control.
For more information, please
visit www.neurobopharma.com.
Contacts:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-november-302303033.html
SOURCE NeuroBo Pharmaceuticals, Inc.